https://www.selleckchem.com/pr....oducts/gsk1120212-jt
0001), and overall survival (OS, P .0001vs .07) and was independently associated with worse LFFR (relative risk [RR] 1.56, 95% CI 1.30-1.9 and OS (RR 1.32, 95% CI 1.07-1.64), after adjusting for clinical covariates. When tested on an independent validation cohort, the gene-signature risk score remained associated with shorter TTF (F-test, P=.002), compared favorably to WHO grade in stratifying cases by OS (P=.003vs P=.1, and was significantly associated with worse OS (RR 1.86, 95% CI 1.19-2.88) on multivariate analy
Like
Comment
Share
